Science Communication Tips for Pharmacists
Drug Topics
NOVEMBER 3, 2022
Pharmacists can help educate patients as they try to analyze scientific information shared via the news or social media.
Thu.Nov 03, 2022
500 
Acumen cruises into the fast lane with novel Alzheimer’s treatment
PharmaVoice
NOVEMBER 3, 2022
The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
What Do the Midterms Mean for Pharmacy?
Drug Topics
NOVEMBER 3, 2022
Independent pharmacists stand to gain—or lose—depending on what happens at the polls in November 2022.
‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected
PharmaVoice
NOVEMBER 3, 2022
Toxoplasmosis is carried by about a third of the world’s population, but effective drugs are lacking — now researchers have discovered a key infection element that could lead to better treatment.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The Vaccine That Prevents Cancer
Drug Topics
NOVEMBER 3, 2022
Human papillomavirus vaccines can help prevent cancern, but uptake still lags.
Proof-of-Concept Study Shows Positive Results for Novel HIV Treatment
Pharmacy Times
NOVEMBER 3, 2022
Investigational broadly neutralizing antibody shows promise as potential as a first-in-class treatment option for HIV.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Study Links Vaping With Reduced Cardiovascular Function
Pharmacy Times
NOVEMBER 3, 2022
Among nicotine users, there was an approximately 4 beat per minute jump in heart rate after vaping or smoking.
Individualizing Care for Patients With Diabetes
Drug Topics
NOVEMBER 3, 2022
Drs Jerry Meece and Jennifer Goldman offer treatment plans based on individualized patient care models for patients with diabetes.
Opinion: How the world can end Covid-19 as a public health threat
STAT
NOVEMBER 3, 2022
The journal Nature published today global consensus recommendations to end Covid-19 as a public health threat. It took a panel of almost 400 independent-thinking scientists, doctors, and representatives of community groups from more than 100 countries (we were among the co-chairs) some 14 months to develop and agree on these recommendations. There have been times when we wondered if it was worth the effort.
Strategies to Educate Patients with Diabetes
Drug Topics
NOVEMBER 3, 2022
Key opinion leaders share strategies to effectively educate patients on diabetes.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Improving the Patient-Pharmacist Relationship in Four Easy Steps
Pharmacy Times
NOVEMBER 3, 2022
Pharmacists are the premier medication experts within health care, who understand more about medication interactions than most physicians and have the unique ability to prevent complications, improve adherence, and save lives.
Here’s why we’re not prepared for the next wave of biotech innovation
STAT
NOVEMBER 3, 2022
T he first time I remember hearing the words “biology’s century,” it was a sales pitch. I was standing by the Long Island Sound in Sachem’s Head, Conn., in the shadow of an 11-foot-tall granite Stonehenge replica built by Jonathan Rothberg, a biotech entrepreneur, as he talked up his newest gadget, a tabletop DNA sequencer.
Study: Black Patients Have Greater Risk of All-Cause Mortality From Diabetes, Stroke
Pharmacy Times
NOVEMBER 3, 2022
Researchers observed disparities in health outcomes between Black individuals and White individuals due to stroke, diabetes, and coronary heart disease.
Telehealth startups prescribing ketamine at home are stirring concern
STAT
NOVEMBER 3, 2022
Since the late ’90s, Kathy Wallace has been battling major depression with a series of drugs — first Prozac, then three others, and back again to Prozac. But in the last six months, nothing seemed to be helping. So her psychiatrist recommended something new: Spravato, a nasal spray approved in 2019 that delivers a drug similar to the hallucinogen ketamine.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Researcher Focuses on Treating Early-Stage Diabetic Kidney Disease Before Kidney Failure
Pharmacy Times
NOVEMBER 3, 2022
Daniel Weiner, MD, MS, associate professor at Tufts University, discusses effective treatment approaches for diabetic kidney disease at ASN Kidney Week.
Opinion: Respiratory infection surge sounds a wake-up call for pediatric emergency care
STAT
NOVEMBER 3, 2022
“M ommy. Daddy. I can’t breathe.” Waking up to those words is terrifying for any parent. For me as a pediatric emergency physician, it was especially scary coming from my 8-year-old son while on a trip in rural New York, hours from a specialized pediatric emergency department dedicated to the care of children. As my son approached our bed, I heard stridor, the high-pitched whistling sound that signals an obstructed airway.
IgA Nephropathy Found to Affect More Young Patients
Pharmacy Times
NOVEMBER 3, 2022
Researcher suggests that medications for high blood pressure may be useful in treating patients with slow-onset IgA nephropathy, a topic he will present on this weekend at ASN Kidney Week in Orlando, Florida.
Could GSK offer the first RSV older adult vaccine?
European Pharmaceutical Review
NOVEMBER 3, 2022
GSK has announced the European Medicines Agency (EMA) has validated a marketing authorisation application (MAA) under accelerated assessment for its respiratory syncytial virus (RSV) vaccine for adults above 60. If approved, the vaccine could be the first vaccine to prevent RSV lower respiratory tract disease (LRTD) in older adults. Accelerated assessment?
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Lecanemab Shows Highly Statistically Significant Reduction of Clinical Decline in Early Alzheimer Disease
Pharmacy Times
NOVEMBER 3, 2022
Eisai plans to file for traditional approval in the United States by March 31, 2023.
Oxy Acne Treatments gain dermatologist-recommended title
Drug Store News
NOVEMBER 3, 2022
Oxy Acne Treatments’ full line of products is now dermatologist-recommended, the company said.
Pharmacists in the Oncology Setting: Financial and Clinical Impact is Significant
Pharmacy Times
NOVEMBER 3, 2022
In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.
Providers of methadone treatment say a big increase in access could backfire
STAT
NOVEMBER 3, 2022
BALTIMORE — Providers of methadone for addiction treatment have a message for advocates seeking a giant expansion in access: Be careful what you wish for. Methadone, they acknowledge, is a highly effective medication for opioid addiction. But allowing doctors to prescribe it directly to patients could backfire, they argue, by leading to an increase in low-quality care or even overdoses on methadone itself.
Clinical Overview: Teprotumumab for Thyroid Eye Disease
Pharmacy Times
NOVEMBER 3, 2022
Teprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.
Global pharma confidence highest on record, shows CPhI Pharma Index
European Pharmaceutical Review
NOVEMBER 3, 2022
Results from CPhI’s 2022 Pharma Index survey , announced at this year’s CPhI Frankfurt, showed pharma confidence in growth , innovation and manufacturing quality has reached record highs, promising positive prospects for the industry in 2023 and beyond. The survey, which offers a collateralised metric of all major categories, acquired data from 400 global pharma companies.
New CDC opioid guidelines emphasize flexibility in treating pain
STAT
NOVEMBER 3, 2022
Federal health officials on Thursday updated their recommendations for using opioids to treat pain, removing specific dose and duration targets that pain experts said had caused unintended harm. The new guidance , released by the Centers for Disease Control and Prevention, reflects the evolution in thinking of how opioids should be used, and the reality of how they are being used.
GSK preps filing for novel antibiotic for urinary tract infections
pharmaphorum
NOVEMBER 3, 2022
In an encouraging development for the fight against antimicrobial resistance (AMR), GSK’s novel antibiotic gepotidacin has shown efficacy in two phase 3 trials, setting up regulatory filings. If approved, gepotidacin (GSK2140944) could become the first drug in a new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in more than 20 years, according to the pharma group, which plans to submit the data to the FDA in the first half of next year.
STAT+: A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines
STAT
NOVEMBER 3, 2022
A leaked draft version of a trade agreement being negotiated between the United Kingdom and India has sparked concern among civil society and patient advocacy groups that the proposed deal would impede the supply of affordable generic medicines in poor countries around the world. At issue is language that would impose changes in patent and regulatory laws in India and, in doing so, contrast with provisions in a World Trade Organization agreement governing the ability of governments to sidestep p
Kantar releases annual PoweRanking report
Drug Store News
NOVEMBER 3, 2022
On the retailer side, Walmart ranked No. 1, followed by Target, while stability remained with Kroger, Amazon and Costco rounding out the Top 5.
Largest-ever trial backs psilocybin treatment for depression
pharmaphorum
NOVEMBER 3, 2022
The psychedelic compound in magic mushrooms – psilocybin – can improve the symptoms of severe depression, according to the largest randomised, controlled trial of the therapy carried out to date. The phase 2 trial investigated a single administration of Compass Pathways’ proprietary Comp360 formulation of synthetic psilocybin given in tandem with psychological support to 233 subjects with depression that had not responded to antidepressant drugs.
Disease prevention-as-a-service: Bringing better health directly to consumers
Drug Store News
NOVEMBER 3, 2022
Vish Kulkarni of Rockley Photonics explains how wearable devices could play a larger role in preventing viruses such as COVID-19 from growing to sever status unnoticed.
When it comes to caring for underserved patients, health tech is still figuring out what success looks like
STAT
NOVEMBER 3, 2022
For startups and investors aiming to bring health technology to underserved populations, evidence of impact should be everything: It’s what shows employers and payers a new offering is worth paying for, and what can help convince patients to give it a try. But while the market is crowded with companies claiming their products meaningfully improve health — especially for underserved groups — there is still no industry-wide standard slate of metrics to fully evaluate them.
Walgreens teams up with its Health Corners, clinic partners to expand access to complimentary diabetes services during Diabetes Awareness Month
Drug Store News
NOVEMBER 3, 2022
Walgreens invests in training to equip pharmacists with expert knowledge to address the specific challenges of this chronic, complex condition.
STAT+: FDA approval decision for Apellis Pharma’s eye disease drug delayed to review more clinical data
STAT
NOVEMBER 3, 2022
Apellis Pharmaceuticals said Thursday that submission of additional clinical data to the Food and Drug Administration will delay the review of its experimental treatment for geographic atrophy — a chronic eye disease and a leading cause of blindness in older people. The FDA was set to announce an approval decision for the Apellis drug on Nov. 26.
Let's personalize your content